Finance

Lists
Outlook: 61.1% bullish·0.0% bearish
Go to analysis
HCA:NYSE
HCA Healthcare Inc
$467.73
-1.15%
(-5.46) 1D
$467.73
0.00% (0.00)
After hours
Closed: Nov 2, 4:00:05 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HCA...
Open
$475.34
High
$477.88
Low
$460.93
Mkt. cap
97.71B
Avg. vol.
1.24M
Volume
32.00
Dividend
0.67%
Quarterly dividend
$0.78
Ex-dividend date
Sep 16, 2026
P/E ratio
15.50
52-wk high
$556.52
52-wk low
$353.99
EPS
$30.19
Beta
1.11
Shares outstanding
208.89M
No. of employees
275K
Open
$475.34
High
$477.88
Low
$460.93
Mkt. cap
97.71B
Avg. vol.
1.24M
Volume
32.00
Dividend
0.67%
Quarterly dividend
$0.78
Ex-dividend date
Sep 16, 2026
P/E ratio
15.50
52-wk high
$556.52
52-wk low
$353.99
EPS
$30.19
Beta
1.11
Shares outstanding
208.89M
No. of employees
275K
News stories
From web sources and news partners
Profile
HCA Healthcare, Inc. is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors. Wikipedia
About HCA Healthcare Inc
CEOSamuel N. Hazen
Employees275K
Founded1968
HeadquartersNashville, Tennessee, United States
SectorHealth care provider
Websitehcahealthcare.com
Analyst ratings
Based on 18 analysts giving stock ratings to HCA in the past 3 months
Buy
Buy
10
Hold
7
Sell
1
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for HCA in the last 3 months.
Highest
Current $467.73
$521.00 (+11.39%)
Average
$464.13 (-0.77%)
Lowest
$380.00 (-18.76%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stephen Baxter
Wells Fargo
Hold
Maintained
$468.00
+0.1%
11/02/2026
Ben Hendrix
RBC Capital
Buy
Maintained
$521.00
+11.4%
10/29/2026
Andrew Mok CFA
Barclays
Hold
Maintained
$401.00
-14.3%
10/29/2026
Ryan Langston
TD Cowen
Buy
Maintained
$486.00
+3.9%
10/28/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
$485.00
+3.7%
10/28/2026
Sean Dodge
BMO Capital
Buy
Reiterated
$495.00
+5.8%
10/28/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
$495.00
+5.8%
10/28/2026
Michael Ha
Robert W. Baird
Hold
Maintained
$409.00
-12.6%
10/28/2026
Matthew Gillmor CFA
KeyBanc
Buy
Maintained
$490.00
+4.8%
10/28/2026
Craig Hettenbach
Morgan Stanley
Sell
Reiterated
$380.00
-18.8%
10/29/2026
Kevin Fischbeck
Bank of America Securities
Hold
Reiterated
$500.00
+6.9%
10/28/2026
Lance Wilkes
Bernstein
Hold
Maintained
$426.00
-8.9%
10/05/2026
Andrew Cooper
Raymond James
Hold
Reiterated
-
-
09/28/2026
Whit Mayo
Leerink Partners
Buy
Reiterated
-
-
09/17/2026
Brian Tanquilut
Jefferies
Buy
Maintained
$450.00
-3.8%
09/17/2026
Benjamin Rossi
J.P. Morgan
Hold
Maintained
$425.00
-9.1%
08/24/2026
Unknown Analyst
Argus Research
Buy
Maintained
$500.00
+6.9%
08/07/2026
David Toung
Argus Research
Buy
Reiterated
$500.00
+6.9%
08/07/2026
David S Macdonald
Truist Financial
Buy
Reiterated
$495.00
+5.8%
08/05/2026
Scott Fidel
Goldman Sachs
Buy
Maintained
$485.00
+3.7%
07/27/2026
A.J. Rice
UBS
Buy
Maintained
$579.00
+23.8%
07/27/2026
Pito Chickering
Deutsche Bank
Buy
Reiterated
$476.00
+1.8%
07/27/2026
Michael Wiederhorn
Oppenheimer
Buy
Maintained
$485.00
+3.7%
07/27/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
$525.00
+12.2%
07/14/2026
Unknown Analyst
Stephens
Buy
Reiterated
$530.00
+13.3%
04/27/2026
Raj Kumar CFA
Stephens
Buy
Reiterated
$530.00
+13.3%
04/27/2026
Courtney Breen
Bernstein
Hold
Maintained
$541.00
+15.7%
03/30/2026
Last report
Oct 27, 2026
Fiscal period
Q3 2026
$7.22 / $6.63
+8.95%beat
Revenue / Est. (USD)
19.85B / 19.33B
+2.70%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
19.51B
19.11B
20.23B
19.85B
Cost of goods sold
11.34B
11.14B
11.18B
11.40B
Cost of revenue
11.34B
11.14B
11.18B
11.40B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.03B
-
-
-
Operating expense
5.00B
5.11B
5.99B
5.50B
Total operating expenses
16.34B
16.25B
17.16B
16.90B
Operating income
3.18B
2.86B
3.07B
2.94B
Other non operating income
-
-
-
-
EBT including unusual items
2.67B
2.29B
2.49B
2.37B
EBT excluding unusual items
2.63B
2.29B
2.48B
2.36B
Income tax expense
509.00M
430.00M
564.00M
521.00M
Effective tax rate
19.05%
18.80%
22.61%
21.98%
Other operating expenses
3.06B
4.18B
5.04B
4.55B
Net income
1.88B
1.62B
1.70B
1.58B
Net profit margin
9.62%
8.48%
8.40%
7.96%
Earnings per share
8.01
7.15
7.59
7.22
Interest and investment income
-
-
-
-
Interest expense
-572.00M
-584.00M
-599.00M
-607.00M
Net interest expenses
-572.00M
-584.00M
-599.00M
-607.00M
Depreciation and amortization charges
911.00M
930.00M
944.00M
954.00M
EBITDA
4.09B
3.79B
4.01B
3.90B
Gain or loss from assets sale
-41.00M
1.00M
-10.00M
-13.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps